Abstract 33P
Background
Evidence highlights the critical role of CD4 T cells in antitumor immunity and immunotherapy. We previously reported that baseline or post-treatment hTERT-specific CD4 Th1 response in blood is associated with the efficacy of immune checkpoint inhibitors (ICI) therapy in patients with advanced melanoma and colorectal cancer (Nardin et al, 2021; Thibaudin et al, 2022). Here, we investigated the involvement of peripheral tumor reactive CD4 Th1 response in durable response to ICI in melanoma patients.
Methods
Blood samples were collected in three groups of advanced melanoma (AJCC8 stage III/IV) patients (pts) according to response to ICI: 50 pts with prolonged disease control (>1 year) (CD[FA1]), 22 pts with primary resistance (R1) defined as no response after 3 months of ICI, and 35 pts with relapsed disease after treatment discontinuation for initial disease control (>1 year) (R2). Multiparametric immunologic analyses were performed using IFN-γ ELISpot, flow cytometry on PBMC and Bulk RNA sequencing on circulating sorted CD4 T cells.
Results
A high frequency of circulating tumor-specific CD4 Th1 response, i.e response against at least one of the 3 antigens tested (hTERT, MAGE-A3 and KK-LC1), was found in all 3 groups (76%, 63%, 68% in CD, R1, R2, respectively). Among the 3 antigens tested, the circulating hTERT-specific CD4 Th1 response frequency was higher in CD compared to R1 and R2 : 70% vs 25% vs 40% positive response (**, p<0.01). Furthermore, CD4 Th1 polyspecific responses, i.e against at least 2 of the 3 antigens tested were more detected in CD pts (31 pts, 62%) compared to 15 (42%) and 7 (32%) pts in R2 and R1 respectively. hTERT-specific CD4 Th1 exhibits cytotoxic phenotype and a modified memory profile compared to non-specific CD4 T cells. Transcriptomic analyses of CD4 T cells revealed 669 genes upregulated and 52 down-regulated in CD pts, mainly enriched in Th1-associated pathways such as IFN-γ response, TNF-α signaling via NF-κB and IL-2-STAT5 signaling compared to healthy donors. Analyses of immune-related genes showed upregulation of cytotoxic markers in CD pts compared to R1 and R2.
Conclusions
In conclusion, our data demonstrated that cytotoxic hTERT-specific CD4 Th1 response is involved in the long-term response to ICI.
Legal entity responsible for the study
CHRU Besançon.
Funding
La ligue contre le cancer; Bourse Chrysalide.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session